Home › Coronary Artery Disease › NCT07087431
Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
PROACT 3: Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
Who can join
Ages 30 to 75 · All sexes
Full eligibility criteria
Inclusion Criteria: * Current age 30-75 years * Established primary care at Mass General Brigham with at least one visit in the last 2 years Exclusion Criteria: \- Currently taking LDL cholesterol- lowering medications, including statins
About the study
The goal of this clinical trial is to evaluate whether disclosure of a polygenic risk score for coronary artery disease (CAD PRS) influences cardiovascular health and risk factor modification over one year among adults aged 30-75 years in the Mass General Brigham primary care network who are not currently taking LDL cholesterol-lowering medications.
What is being tested
- Immediate disclosure of CAD PRS results (behavioral)
- Deferred Disclosure of CAD PRS results (behavioral)
Sponsor: Massachusetts General Hospital · Participants: 500 · Started: Oct 15, 2025
Contact the study team
- Roukoz Karam, MD · Phone: 6174121147
Official record on ClinicalTrials.gov — NCT07087431
Locations in the U.S.
| Massachusetts | Massachusetts General Hospital, Boston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.